IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

PLYMOUTH, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...